dl-4-hydroxy-4-(4-fluorophenyl)butyric acid | 87545-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dl-4-hydroxy-4-(4-fluorophenyl)butyric acid
• 英文别名: 4-(4-fluorophenyl)-4-hydroxybutanoic acid
• CAS: 87545-51-5
• 化学式: C₁₀H₁₁FO₃
• 分子量: 198.194
• InChiKey: UOBOSSRBVANWMD-UHFFFAOYSA-N

物化性质

• 沸点：
  362.7±32.0 °C(Predicted)
• 密度：
  1.300±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  dl-4-hydroxy-4-(4-fluorophenyl)butyric acid 在 lithium aluminium tetrahydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙酸乙酯 、 乙腈 为溶剂， 反应 4.67h， 生成 (R)-4-[(4aS,9bS)-8-Fluoro-5-(4-fluoro-phenyl)-1,3,4,4a,5,9b-hexahydro-pyrido[4,3-b]indol-2-yl]-1-(4-fluoro-phenyl)-butan-1-ol
  参考文献：
  名称：

  Neuroleptic activity of chiral trans-hexahydro-.gamma.-carbolines

  摘要：

  A series of trans-8-fluoro-5-(4-fluorophenyl)-2,3,4,4a,5, 9b-hexahydro-1H-pyrido[4,3-b]indoles with various N-2 substituents has been prepared and tested for neuroleptic activity [( 3H]spiroperidol binding and amphetamine antagonism). Several members of this series showed exceptional in vivo potency, especially the hydantoin derivatives 27-30. Resolution into the enantiomers showed that neuroleptic activity is associated with the 4aS,9bS absolute configuration. These rigid neuroleptics have been correlated with other rigid neuroleptics [(+)-dexclamol, Ro 22-1319] and can serve to further define the topography of the dopamine receptor.

  DOI：

  10.1021/jm00151a002
• 作为产物：
  描述：

  5-(4-氟苯基)-4,5-二氢-2(3H)-呋喃酮 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 0.67h， 生成 dl-4-hydroxy-4-(4-fluorophenyl)butyric acid
  参考文献：
  名称：

  Neuroleptic activity of chiral trans-hexahydro-.gamma.-carbolines

  摘要：

  A series of trans-8-fluoro-5-(4-fluorophenyl)-2,3,4,4a,5, 9b-hexahydro-1H-pyrido[4,3-b]indoles with various N-2 substituents has been prepared and tested for neuroleptic activity [( 3H]spiroperidol binding and amphetamine antagonism). Several members of this series showed exceptional in vivo potency, especially the hydantoin derivatives 27-30. Resolution into the enantiomers showed that neuroleptic activity is associated with the 4aS,9bS absolute configuration. These rigid neuroleptics have been correlated with other rigid neuroleptics [(+)-dexclamol, Ro 22-1319] and can serve to further define the topography of the dopamine receptor.

  DOI：

  10.1021/jm00151a002

文献信息

• Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
  申请人：Johnson Alan T.

  公开号：US20100286125A1

  公开（公告）日：2010-11-11

  Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.

  具有以下式的化合物是4-苯基-4-羟基丁酸的羟肟酸衍生物，能够抑制炭疽细菌感染的致命效应，并且在炭疽中毒的治疗中有用。
• [EN] PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF<br/>[FR] ACIDE HYDROXAMIQUE SUBSTITUÉ PAR UN GROUPE PYRIDIN-2-YLALKYLAMINO ET SES UTILISATIONS
  申请人：HAWAII BIOTECH INC

  公开号：WO2019178063A1

  公开（公告）日：2019-09-19

  Compounds of formula I are provided: wherein X is NH, or CH2, Y is a single bond, or -CHR5-, R1 is H, C1-C4 alkyl, or C1-C4 hydroxyalkyl, R2 and R2' are each independently H, C1-C4 alkyl, or C1-C4 hydroxyalkyl, each R3 is independently H, halo, -CF3, C1-C4 alkyl, or C1-C4 alkoxy, C3 perhaloalkyl, each R4 is independently H, halo, or C1-C4 alkyl, R5 is C1-C4 alkoxy, r is integer from 0 to 3; and p is integer from 0 to 3.

  提供了式I的化合物：其中X为NH或CH2，Y为单键或-CHR5-，R1为H、C1-C4烷基或C1-C4羟基烷基，R2和R2'各自独立地为H、C1-C4烷基或C1-C4羟基烷基，每个R3独立地为H、卤素、-CF3、C1-C4烷基或C1-C4烷氧基，C3全氟烷基，每个R4独立地为H、卤素或C1-C4烷基，R5为C1-C4烷氧基，r为0到3之间的整数；p为0到3之间的整数。
• [EN] QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS POUR TRAITER DES MALADIES INFLAMMATOIRES ET ALLERGIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2009050204A1

  公开（公告）日：2009-04-23

  The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

  本发明涉及式(I)的化合物及其盐，其制备方法，含有它们的组合物以及它们在治疗各种疾病（如过敏性鼻炎）中的应用。
• 2-Substitute
  申请人：Pfizer Inc.

  公开号：US04224329A1

  公开（公告）日：1980-09-23

  2-Substituted-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles of the formula (I): ##STR1## and the pharmaceutically-acceptable salts thereof, wherein the hydrogen atoms in the 4a position and 9b positions are in a trans relationship to each other and the 5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole moiety is dextrorotatory; X.sub.1 and Y.sub.1 are the same or different and are each hydrogen or fluoro; Z.sub.1 is hydrogen, fluoro or methoxy; M is a member selected from the group consisting of ##STR2## a mixture thereof and C.dbd.O and n is 3 or 4; their use as tranquilizing agents, pharmaceutical compositions containing them and a process for their production.

  式(I)中的2-取代-5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚及其药学上可接受的盐，其中4a位和9b位的氢原子相对构型为反式，5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚基团为右旋性；X1和Y1相同或不同，分别为氢或氟；Z1为氢、氟或甲氧基；M为从以下组中选择的成员：##STR2## 其混合物和C.dbd.O，n为3或4；它们作为镇静剂的用途，包含它们的制药组合物以及它们的制备过程。
• 2-Substituted-trans-5-ar
  申请人：Pfizer Inc.

  公开号：US04252812A1

  公开（公告）日：1981-02-24

  2-Substituted-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles of the formula (I): ##STR1## and the pharmaceutically-acceptable salts thereof, wherein the hydrogen atoms in the 4a position and 9b positions are in a trans relationship to each other and the 5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole moiety is dextrorotatory; X.sub.1 and Y.sub.1 are the same or different and are each hydrogen or fluoro; Z.sub.1 is hydrogen, fluoro or methoxy; M is a member selected from the group consisting of ##STR2## a mixture thereof and C=0 and n is 3 or 4; their use as tranquilizing agents, pharmaceutical compositions containing them and a process for their production.

  式(I)的2-取代-5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚及其药学上可接受的盐，其中4a位和9b位的氢原子相对构型为反式，5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚基团为右旋性；X.sub.1和Y.sub.1相同或不同，分别为氢或氟；Z.sub.1为氢、氟或甲氧基；M为从以下组中选择的成员之一：##STR2## 其混合物和C=0，n为3或4；它们作为镇静剂的用途，包含它们的制药组合物以及它们的制备方法。